Brokerages Set Zevra Therapeutics, Inc. (NASDAQ:ZVRA) PT at $20.83

Shares of Zevra Therapeutics, Inc. (NASDAQ:ZVRA) have been given a consensus recommendation of “Buy” by the eight research firms that are currently covering the company, MarketBeat reports. Seven analysts have rated the stock with a buy recommendation and one has issued a strong buy recommendation on the company. The average twelve-month price objective among brokers that have updated their coverage on the stock in the last year is $20.83.

Several brokerages recently weighed in on ZVRA. HC Wainwright reissued a “buy” rating and issued a $20.00 target price on shares of Zevra Therapeutics in a research note on Monday, September 30th. Roth Mkm boosted their target price on shares of Zevra Therapeutics from $19.00 to $21.00 and gave the company a “buy” rating in a research note on Tuesday, September 24th. Guggenheim began coverage on shares of Zevra Therapeutics in a research note on Monday, October 7th. They issued a “buy” rating and a $20.00 target price for the company. JMP Securities started coverage on shares of Zevra Therapeutics in a research note on Tuesday, September 24th. They issued an “outperform” rating and a $17.00 target price for the company. Finally, Canaccord Genuity Group dropped their price objective on shares of Zevra Therapeutics from $24.00 to $22.00 and set a “buy” rating for the company in a research note on Wednesday, September 18th.

Hedge Funds Weigh In On Zevra Therapeutics

Institutional investors have recently made changes to their positions in the business. Price T Rowe Associates Inc. MD acquired a new position in Zevra Therapeutics in the first quarter valued at about $64,000. The Manufacturers Life Insurance Company boosted its holdings in shares of Zevra Therapeutics by 15.2% during the second quarter. The Manufacturers Life Insurance Company now owns 18,573 shares of the company’s stock worth $91,000 after purchasing an additional 2,452 shares during the period. SG Americas Securities LLC acquired a new position in Zevra Therapeutics in the 3rd quarter valued at $105,000. City State Bank boosted its position in shares of Zevra Therapeutics by 14.1% during the 3rd quarter. City State Bank now owns 16,224 shares of the company’s stock valued at $113,000 after acquiring an additional 2,000 shares in the last quarter. Finally, Virtu Financial LLC acquired a new position in Zevra Therapeutics in the fourth quarter worth $177,000. 35.03% of the stock is owned by institutional investors and hedge funds.

Zevra Therapeutics Price Performance

Shares of NASDAQ ZVRA opened at $8.38 on Friday. The firm has a market capitalization of $350.73 million, a P/E ratio of -6.21 and a beta of 1.94. Zevra Therapeutics has a one year low of $3.89 and a one year high of $8.95. The company’s fifty day moving average is $7.45 and its two-hundred day moving average is $5.89. The company has a debt-to-equity ratio of 1.80, a quick ratio of 2.00 and a current ratio of 2.00.

Zevra Therapeutics (NASDAQ:ZVRA) last released its quarterly earnings results on Tuesday, August 13th. The company reported ($0.48) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.47) by ($0.01). The firm had revenue of $4.45 million for the quarter, compared to analyst estimates of $4.08 million. Zevra Therapeutics had a negative return on equity of 124.85% and a negative net margin of 274.10%. During the same period last year, the firm earned ($0.15) EPS. Analysts forecast that Zevra Therapeutics will post -1.63 EPS for the current fiscal year.

Zevra Therapeutics Company Profile

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.